Biogen’s Gene Therapy Strikes Out in Retinitis Pigmentosa TrialAdeno-Associated Virus (AAV), Biogen, Blindness, Clinical Trials, Gene Therapy, R&D, Rare Inherited Diseases, Vision Loss, X-Linked Retinitis Pigmentosa (XLRP)Biogen reported that the company’s gene therapy, cotoretigene toliparvovec, failed to hit the primary endpoint of the Phase II/III XIRIUS trial for X-linked retinitis pigmentosa (XLRP). Read more May 14, 2021/by Andrew Humphreys https://www.pharmalive.com/wp-content/uploads/2021/05/Biogens-Gene-Therapy-Strikes-Out-in-Phase-IIIII-Retinitis-Pigmentosa-Trial-BioSpace-5-14-21.jpeg 350 625 Andrew Humphreys https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png Andrew Humphreys2021-05-14 11:14:432021-05-14 11:19:53Biogen’s Gene Therapy Strikes Out in Retinitis Pigmentosa Trial